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Abstract
Optical coherence tomography angiography (OCT-A) is a non-invasive, non-dye-based imagingmodality that has the potential to
enhance our understanding of retinal diseases. While this rapidly advancing imaging modality offers great potential, there is a
need for community-wide understanding of the range of technologies and methods for interpreting the images, as well as a need
to enhance understanding of images from disease-free eyes for reference when screening for retinal diseases. Importantly, clinical
trials have been designed without OCT-A-based endpoints; therefore, caution is required when making treatment decisions based
on OCT-A imaging alone. With this in mind, a full understanding of the advantages and limitations of OCT-Awill be vital for
effective development of the technique within the field of ophthalmology. On behalf of the Vision Academy Steering Committee
(sponsored by Bayer), this publication summarizes the views of the authors on the current use of OCT-A imaging and explores its
potential for future applications in research and clinical practice.
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Introduction
Optical coherence tomography (OCT) has progressed rapidly
since its implementation in the field of ophthalmology. It is
becoming a widely used imaging tool in the diagnosis of cho-
roidal neovascularization (CNV) or macular edema in
different retinal and choroidal diseases. Using the same tech-
nology, OCT angiography (OCT-A) was introduced as a
means for visualizing retinal and choroidal vasculature.
Unlike fluorescein angiography (FA) and indocyanine green
angiography (ICGA), which use intravenous dyes to fill the
fundus vasculature and permit its visualisation, OCT-A uti-
lizes motion-contrast imaging, calculating differences in
backscattered OCT signal intensity between sequential scans
of the same area [1–3]. This non-invasive ocular imaging
technique can resolve the distances of reflective structures
within tissues, producing high-resolution, cross-sectional
scans of vascular flow in seconds [2–4]. However, there is,
as yet, little consensus within the retinal specialist community
on the appropriate use of OCT-A for diagnosis or monitoring,
and current treatment recommendations state that the use of
OCT-A is not essential for good patient management.
As an emerging technology that could potentially have a
significant impact on the clinical management of retinal dis-
ease, the technique of OCT-A falls within the scope of the
Vision Academy. The Vision Academy is an initiative that
brings together global leaders in ophthalmology, providing a
forum to share existing skills and knowledge. With defined
activity programs, the Vision Academy seeks to address key
unmet needs in the field of retinal disease, providing outputs
to build best practice and lead the wider community in the
drive towards optimized, compassionate patient care.
Francisco J. Rodríguez and Giovanni Staurenghi are also members of the
Vision Academy Steering Committee.
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Members of the Vision Academy Steering Committee (see
“Acknowledgments” section) met in 2016 to discuss the use
of OCT-A for the management of retinal disease, with partic-
ular focus on its current utility, limitations, and potential for
future application in research and clinical practice. In this re-
view, we summarize the views of the Vision Academy
Steering Committee, focusing on the use of OCT-A in
neovascular age-related macular degeneration (nAMD).
Understanding the challenges of OCT-A
OCT-A imaging provides a detailed view of retinal vascula-
ture for qualitative and quantitative analysis of retinal structure
and microvascular function [2]. Unlike FA and ICGA, OCT-A
has the ability to easily segment different layers of the retina,
making it an exciting tool for developing our understanding of
retinal diseases [2]. However, without official guidance for
OCT-A use in retinal disease management, there remains a
lack of clarity on the appropriate interpretation of disease
characteristics, as well as a lack of understanding of ‘normal’
OCT-A images of disease-free eyes for use as a reference point
when making diagnoses and treatment decisions.
Despite only emerging in recent years, OCT-A is already
widely used in clinical practice and is increasingly used as a
diagnostic tool for retinal disease; for example, OCT-A can be
used to identify the presence of CNV in nAMD and to identify
areas of non-perfusion associated with diabetic retinopathy
[2]. However, the technology is advancing at a much greater
rate than the retinal specialist community’s experience of the
technique, an issue that is confounded by the wide range of
OCT-A technologies available. Currently, there are a number
of available methods for OCT-A image acquisition, including
amplitude-decorrelation and phase-variance algorithms
(Table 1), as well as two methods for OCT-A image averaging
[4–8, 12]. Figure 1 shows images of the microvasculature of a
healthy retina in one patient, taken using a range of OCT-A
technologies available on the market.
While OCT-A is not considered essential for good patient
management, retinal centers will inevitably feel under pres-
sure to follow the OCT-A trend. In recent years, there has been
an exponential increase in the number of publications on
OCT-A in the context of retinal disease, reflecting the interest
of the clinical community in this technology.
OCT-A in combination with structural OCT has been
shown to be more effective than either FA or OCT-A alone
for the evaluation of macular complications associated with
retinal disease [13]. However, there is a growing concern
that physicians may be making treatment decisions based on
OCT-A alone, which could have a detrimental effect on patient
care. While the acquisition of OCT-A scans is fast, image inter-
pretation can be time-consuming, with the need to analyze data
from all available B-scans and the entire retinal slab to reliably
avoid misinterpretation of image artifacts [1]. Furthermore, it
remains unclear whether OCT-A is useful in all cases, or if it is
better suited to particular subgroups of patients with retinal
disease and specific pathologies. This situation is further com-
plicated by the number of OCT-A technologies available; each
has its own advantages and limitations when imaging different
retinal disease pathologies, yet there is no clear consensus on
which patient subgroups they are most suited to.
Rather than attempting to identify a superior technology
from the OCT-A platforms available, our focus should instead
be on optimizing the use of existing equipment and accurately
interpreting the resulting scans. Currently, there are no stan-
dardized protocols for image acquisition, although some
physicians are employing their own protocols, using the
specific OCT-A platform in their center. With little shared
community-wide experience of image interpretation, a lack
of defined protocols may lead to inconsistencies in clinical
practice.
A major benefit for OCT-A is its ability to scan the deep
tissue layers of the eye, notably the choroid [1]. However, it is
often challenging to quantify retinal morphology in patients
with nAMD presenting with fibrovascular pigment epithelial
detachment (PED) or mixed fibrovascular PED, or abnormal-
ities of choroidal microvasculature in cases of CNV. Figure 2
demonstrates the visual capabilities of a range of different
OCT-A algorithms utilized in clinical practice to resolve struc-
tures across multiple tissue levels, including their ability to
visualize deep regions of neovascularization in the choroid
(bottom row). Upgrades in software for image processing
and visualization are continuously being produced and are
improving the quality of OCT-A images. However, variation
in image quality across different OCT-A algorithms further
highlights the need for standardized protocols for imaging
the different retinal layers in each disease indication.
OCT-A as a complementary diagnostic tool
The effectiveness of OCT-A has been demonstrated in princi-
ple for the diagnosis of CNV in patients with nAMD [14].
OCT-A is an additional technique in the current portfolio of
imaging modalities, with potential for use alongside FA,
ICGA, and conventional OCT as part of a multimodal diag-
nostic process for optimal evaluation of disease prognosis.
While current treatment guidelines state that OCT-A is not
essential for effective patient management, it could prove a
useful tool for physicians who currently make retreatment
decisions without the use of an angiogram. For physicians
who already use angiography to inform their treatment deci-
sions, OCT-A should be considered a useful complementary
technique that can provide additional information for diagno-
sis. OCT-A imaging of subjects who were previously diag-
nosed using more traditional methods (such as FA or
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conventional OCT) may ultimately lead to a change in diag-
nostic algorithms based on the additional information avail-
able from the resulting images (see Fig. 3).
Current limitations of OCT-A imaging
in retinal disease
Several practical limitations of OCT-A require further
consideration.
In a study of healthy subjects, Matsunaga et al. demonstrated
that 3 × 3 mmOCT-A images are at least equivalent in quality to
scans obtained using FA [15]. However, a small scan size, with a
limited field of view, may limit the use of OCT-A for disease
screening. While the standard imaging area of the retinal surface
with OCT-A is 3 × 3 mm, some physicians are opting to acquire
larger scan sizes, e.g. 6 × 6 mm or 8 × 8 mm [2]. However, a
widened field of view may decrease the image quality because
some software utilizes the same number of B-scans across all
scanning areas [2]. In order to achieve a field of view of the same
size as these traditional imaging techniqueswhile retaining a high
Optovue AngioVue™ ZEISS PLEX™ EliteZEISS AngioPlex™ Topcon Triton SS OCT Angio™
NIDEK RS-3000 Advance Heidelberg SPECTRALIS Canon Angio eXpert Optopol OCT
Fig. 1 Images of normal retinal microvasculature taken using a range of available OCT-A technologies. OCT optical coherence tomography, OCT-A
optical coherence tomography angiography, SS OCT swept-source optical coherence tomography. Source: Images provided by Giovanni Staurenghi
Table 1 A summary of available algorithms for OCT-A imaging
OCT-A algorithm Definition Developer (OCT device)
OMAG [5–7] Optical microangiography ZEISS (AngioPlex™)/University of
Washington
CODAA [8] Complex OCT signal differential analysis angiography NIDEK (AngioScan)
SSADA [2, 4–7, 9] Split-spectrum amplitude-decorrelation angiography Optovue (AngioVue™)
FSADA [6] Full-spectrum amplitude-decorrelation angiography Canon (Angio eXpert)
SPECTRALIS® OCT-A
[6]
Full-spectrum probabilistic approach Heidelberg Engineering (SPECTRALIS®)
OCTARA [6] OCT angiography ratio analysis Topcon (Triton SS OCTAngio™)
PRD-OCT [10] Phase-resolved Doppler OCT University of Amsterdam
PV-OCT [6] Phase-variance OCT California Institute of Technology
UHS SS OCT [11] Ultra-high-speed swept-source OCTwith variable interscan time analysis
(VISTA)
Massachusetts Institute of Technology
OCT optical coherence tomography, OCT-A optical coherence tomography angiography
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level of resolution, physicians may have to stitch together multi-
ple images, using montage OCT-A, to visualize areas of the
retinal vasculature [16, 17].
OCT-A imaging can only detect blood flow above a mini-
mum threshold, since it relies on differences between consec-
utive OCT B-scans to determine flow. With current OCT-A
technologies, increasing the time interval between consecutive
B-scans would greatly increase the risk of artifacts caused by
eye motion, resulting in a limited ability to detect slowly
flowing structures (which are often seen in cases of
microaneurysm or fibrotic CNV) [2]. Instead, in some cases
where a slowly flowing lesion is not visualized using the first
and second OCT B-scans, the high-speed scanning capabili-
ties of OCT-A systems that utilize variable interscan time
analysis (VISTA) allow an image to be processed using the
first and third B-scans, thereby decreasing the minimum
threshold without increasing the risk of motion artifacts [2].
Similarly, restricted visualization of slow-filling polyps
may limit the reliability of OCT-A for use as a primary diag-
nostic tool in patients with polypoidal choroidal vasculopathy;
however, a study by Inoue et al. demonstrated the potential for
combining en face and cross-sectional OCT-A to resolve
polypoidal structures [18].
Another limitation of OCT-A may be its inability to accu-
rately determine the extent of vascular leakage. This could
limit the use of OCT-A alone in the identification of changes
in vascular permeability associated with diseases such as
nAMD, diabetic macular edema, and retinal vein occlusion.
OCT-A imaging artifacts
An understanding of OCT-A image artifacts is essential for
accurate assessment of retinal disease pathologies. There are
a number of known causes of OCT-A image artifacts, includ-
ing distortions caused by errors in image processing and dis-
play, or ocular motion (Fig. 4) [19]. Certain characteristics of
the eye may also cause artifacts; for example, given the high
prevalence of myopia among patients, eyes may have a high
refractive error and OCT-A light beams may be non-
perpendicular to the retinal surface [19].
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Fig. 2 Microvasculature resolution in the superficial and deep retinal
vessels of normal subjects (a and b, respectively), and the choroidal
layer of a patient with CNV (c), visualized using a range of available
OCT-A algorithms. CNV choroidal neovascularization, FSADA full-
spectrum amplitude-decorrelation angiography, OMAG optical
microangiography, SSADA split-spectrum amplitude-decorrelation
angiography. Source: Presented by Giovanni Staurenghi at the Vision
Academy Annual Meeting 2016; Barcelona, Spain, March 12–13, 2016
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Figure 4a demonstrates image distortion caused by ocular
motion, revealing doubling of retinal vasculature and a subse-
quent inability to produce a valid assessment of disease pa-
thology. While this remains a limitation of OCT-A, software-
based motion correction methods have been developed to
manage image distortions caused by eye movement; however,
these can introduce criss-cross image defects (Fig. 4c) [19,
20].
Prominent media and vitreous opacities (‘floaters’), as well
as superficial retinal vessels, can cause shadow artifacts, mak-
ing it difficult to clearly visualize the deeper retinal layers
(Fig. 4d) [9, 19]. Additionally, this segmentation process fails
to work effectively in cases where the retinal architecture is
altered, e.g. by edema, atrophy or subretinal hemorrhage
(Fig. 4b) [19].
Projection artifacts are caused by interference from super-
ficial vessels during visualization of deeper tissue structures
and are nearly always present in any structure that appears
below vasculature (Fig. 5) [19]. As a result, visualization of
the corresponding B-scan is required alongside the OCT-A
blood flow image for accurate interpretation. Built-in software
to correct segmentation error, whereby the OCT-A software
corrects for projection artifacts using an automated segmenta-
tion process, is under evaluation; however, there is concern
that some of the information may be lost, or new sets of image
artifacts may be introduced, ultimately leading to misinterpre-
tation by the physician [19].
Opportunities for OCT-A
Despite the current limitations of OCT-A, it offers a number of
potential opportunities to improve the accuracy of diagnosis in
clinical practice and the understanding of certain conditions.
Accurate identification of the choroidal neovascular mem-
brane within an area of subretinal fluid could provide an in-
sight into the nature of chronic central serous retinopathy, an
insufficiently understood condition (thought to be caused by
retinal pigment epithelium dysfunction or choroidal
hyperpermeability) that leads to fluid accumulation in the
subretinal space [21]. The deep-penetrating capabilities of
OCT-A offer the opportunity to study differences between
deep and superficial blood vessels that cannot be easily dis-
tinguished by FA alone.
As a non-invasive technique, OCT-A is suited to cases
where dye-based techniques are not appropriate because of
patient allergy, or where accurate assessment may be difficult
(in which case OCT-A could be used as an additional tool to
better interpret the ICGA image). While FA and ICGA are
generally considered to be safe techniques, the intravenous
Fig. 3 A case study of a patient presenting with visual loss in the right
eye, demonstrating a change in overall diagnosis after implementation of
OCT-A as part of a multimodal imaging approach. Retinal imaging was
provided by a color fundus photography, b FA, c ICGA, and d, e OCT,
and led to an initial diagnosis of suspicious CNV (regions marked
with dotted and dashed lines in images b and c). Further imaging by
f, g OCT-A led to a final diagnosis of two different CNVs: one active
(dotted line) and one inactive (dashed line) in AMD. In image a, arrows 1
and 2 represent the locations of cross-sectional B-scans (images d and e,
respectively). AMD age-related macular degeneration, CNV choroidal
neovascularization, FA fluorescein angiography, ICGA indocyanine
green angiography, OCT optical coherence tomography, OCT-A optical
coherence tomography angiography. Source: Images provided by
Giovanni Staurenghi
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dyes used for vascular imaging are contraindicated in preg-
nancy and may also pose the risk of mild to moderate adverse
reactions, e.g. nausea, vomiting, urticaria, and even severe
cases of anaphylaxis [2, 22]. The rapid nature of OCT-A
Fig. 4 OCT-A imaging
distortions caused by a ocular
motion, revealing loss of detail
despite the high signal score, with
apparent doubling of vessels; b
segmentation failure, leading to
visualization of vessels from
different layers in one image that
does not reflect actual anatomy; c
criss-cross image defects
introduced after software-based
motion correlation to compensate
for ocular motion artifacts; d
intrinsic properties of the eye,
such as vitreous ‘floaters’,
causing a loss of signal with
media opacity. Yellow arrows
indicate regions of interest.
OCT-A optical coherence
tomography angiography. Source:
Images provided by Giovanni
Staurenghi
Fig. 5 Projection artifacts seen with OCT-A imaging of different tissue
layers. a At the level of the retinal pigment epithelium, retinal vessels are
seen because of projection artifacts. b When scanning at the level of the
choriocapillaris, the image is still dominated by retinal vasculature
projection. c Scanning further back into the choroid reveals less
projection of retinal vasculature. Please note that the best image of the
CNV is obtained using the projection artifact of the same CNV. CNV
choroidal neovascularization, OCT-A optical coherence tomography
angiography. Source: Images provided by Giovanni Staurenghi
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image acquisition also makes it ideal for use in cases where
the more time-consuming FA and ICGA are not indicated.
However, its inability to accurately detect areas of leakage,
fluid accumulation, or slow-flowing microaneurysms current-
ly limits its use as the sole diagnostic tool for the majority of
macular conditions.
OCT-based imaging biomarkers provide a valuable tool for
detecting the early stages of progression of ocular diseases
[23]. Moreover, the increasing use of OCT-A in clinical trials
and clinical practice may have the potential to identify novel
biomarkers for the different retinal diseases [23]. Additionally,
in subsets of patients without accumulation of subretinal fluid,
OCT-A may provide an important tool for identification of
deeper pathologies. There may also be scope for
implementing OCT-A imaging for specific pathologies (such
as subretinal hyperreflective material lesions) occasionally
seen in patients treated for CNV secondary to AMD, provid-
ing a potentially useful tool for monitoring disease activity
and response to treatment [24].
Implementation of OCT-A technology into a multimodal
platform, alongside other established imaging techniques, may
provide us with a greater understanding of disease pathways by
allowing more accurate assessment of the retinal and choroidal
layer microvasculature. For example, Inoue et al. showed that
the sensitivity for detecting type 1 neovascularization using
combined data from OCT-A and conventional OCT imaging
was significantly greater than the sensitivities of either OCT-A
or FA imaging alone [13].
Conclusions
OCT-A is a non-invasive imaging technique with great poten-
tial for use in clinical practice. Evidence has demonstrated the
effectiveness of OCT-A as an additional tool for retinal disease
diagnosis, but its role in disease monitoring remains unclear.
With its current practical limitations, considerations must be
made regarding how suitable it would be as a primary tool for
diagnosis of retinal disease. There is currently no clear con-
sensus on whether OCT-A is useful in all cases or better suited
to particular subgroups of patients with retinal disease. At this
stage in its development, OCT-A should be considered a com-
plementary diagnostic tool alongside already established im-
aging modalities, with potential for use in special cases where
invasive imaging techniques are inappropriate. While OCT-A
imaging is already widely employed in clinical practice, the
technology is advancing at a much faster rate than the
community’s understanding of and experience with the tech-
nique. As advances in OCT-A technology continue to prog-
ress, current areas with gaps in knowledge will need to be
addressed; the need for standard protocols for OCT-A image
acquisition and interpretation, with standardization across all
competing OCT-A technologies, has been suggested as the
area for primary future focus. Additionally, as OCT-A does
not detect leakage, meaning it is not currently possible to
differentiate the morphological features of leakage from vas-
cular perfusion, further information is required on the accurate
identification of image artifacts to reliably measure signals
showing vascular perfusion and to discern between perfusion
and leakage.
As a newly developed technology, ongoing research activ-
ity should help define best practice for OCT-A in various
retinal diseases. Moreover, through integration of qualitative
and quantitative OCT-A parameters into clinical trial end-
points, the community-wide understanding of OCT-A tech-
nology as a tool for monitoring responses to treatment and
guiding treatment decisions could be greatly enhanced.
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